DENGUE

January, 2005

    Diagnosis, Diagnostics, Immunodiagnosis & Immunodiagnostics:

10915.   De Paula SO, de Melo Lima C, Torres MP, Pereira MR, Lopes da Fonseca BA. One-Step RT-PCR protocols improve the rate of dengue diagnosis compared to Two-Step RT-PCR approaches. J Clin Virol. 2004 Aug;30(4):297-301.

10916.   Lemmer K, Donoso Mantke O, Bae HG, Groen J, Drosten C, Niedrig M. External quality control assessment in PCR diagnostics of dengue virus infections. J Clin Virol. 2004 Aug;30(4):291-6.

Back

 April, 2005

 

Diagnosis, Diagnostics, Immunodiagnosis & Immunodiagnostics:  

11368.    Chanama S, Anantapreecha S, A-nuegoonpipat A, Sa-gnasang A, Kurane I, Sawanpanyalert P. Analysis of specific IgM responses in secondary dengue virus infections: levels and positive rates in comparison with primary infections.J Clin Virol. 2004 Nov;31(3):185-9.

11369.  Goncalvez AP, Men R, Wernly C, Purcell RH, Lai CJ. Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses.J Virol. 2004 Dec;78(23):12910-8.

11370.   Hogrefe WR, Moore R, Lape-Nixon M, Wagner M, Prince HE. Performance of immunoglobulin G (IgG) and IgM enzyme-linked immunosorbent assays using a West Nile virus recombinant antigen (preM/E) for detection of West Nile virus- and other flavivirus-specific antibodies.J Clin Microbiol. 2004 Oct;42(10):4641-8.

11371.   Saito M, Oishi K, Inoue S, Dimaano EM, Alera MT, Robles AM, Estrella BD Jr, Kumatori A, Moji K, Alonzo MT, Buerano CC, Matias RR, Morita K, Natividad FF, Nagatake T. Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections. Clin Exp Immunol. 2004 Nov;138(2):299-303.

11372.  Schilling S, Ludolfs D, Van An L, Schmitz H. Laboratory diagnosis of primary and secondary dengue infection.J Clin Virol. 2004 Nov;31(3):179-84.

11373.  Shah I, Deshpande GC, Tardeja PN. Outbreak of dengue in Mumbai and predictive markers for dengue shock syndrome.J Trop Pediatr. 2004 Oct;50(5):301-5.

Pathogenesis:

11374.  Laille M, Roche C. Comparison of dengue-1 virus envelope glycoprotein gene sequences from French Polynesia.Am J Trop Med Hyg. 2004 Oct;71(4):478-84.

11375.  Lin SR, Hsieh SC, Yueh YY, Lin TH, Chao DY, Chen WJ, King CC, Wang WK. Study of sequence variation of dengue type 3 virus in naturally infected mosquitoes and human hosts: implications for transmission and evolution.J Virol. 2004 Nov;78(22):12717-21.
Therapy:

11376.   Goel A, Patel DN; Lakhani KK, Agarwal SB, Agarwal A, Singla S, Agarwal R. Dengue fever: a dangerous foe. Journal, Indian Academy of Clinical Medicine. 2004 Jul-Sept; 5(3): 247-258.

                                                               Back

  
 

 July, 2005

Diagnosis, Diagnostics, Immunodiagnosis & Immunodiagnostics:  

  1. Gupta E, Dar L, Narang P, Srivastava VK, Broor S. Serodiagnosis of dengue during an outbreak at a tertiary care hospital in Delhi. Indian J Med Res. 2005 Jan;121(1):36-8.

  2. Kao CL, King CC, Chao DY, Wu HL, Chang GJ. Laboratory diagnosis of dengue virus infection: current and future perspectives in clinical diagnosis and public health. J Microbiol Immunol Infect. 2005 Feb;38(1):5-16. Review.

  3. Lee IK, Liu JW, Yang KD.  Clinical characteristics and risk factors for concurrent bacteremia in adults with dengue hemorrhagic fever. Am J Trop Med Hyg. 2005 Feb;72(2):221-6. 
Pathogenesis:

  1. Halstead SB, Heinz FX, Barrett AD, Roehrig JT. Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria. Vaccine. 2005 Jan 4;23(7):849-56. 
Vaccines:

  1. Edelman R. Dengue and dengue vaccines. J Infect Dis. 2005 Mar 1;191(5):650-3.

Therapy:

  1. Hales S, van Panhuis W. A new strategy for dengue control. Lancet. 2005 Feb 12;365(9459):551-2.

  2. Ligon BL. Dengue fever and dengue hemorrhagic fever: a review of the history, transmission, treatment, and prevention. Semin Pediatr Infect Dis. 2005 Jan;16(1):60-5. Review. 

Back

October, 2005

 

Some Selected Abstracts:

1.

 Hombach J, Barrett AD, Cardosa MJ, Deubel V, Guzman M, Kurane I, Roehrig JT, Sabchareon A, Kieny MP. Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. Vaccine. 2005 Apr 15;23(21):2689-95.

Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland. hombachj@who.int

In light of the continuous spread of human pathogenic flaviviruses, in particular the mosquito-transmitted species, vaccine development remains a high priority on the public health agenda. On 26-27 April 2004, a conference was held in Bangkok, Thailand, to review current status of flavivirus vaccine development and related issues, focussing on dengue (DEN) and Japanese encephalitis (JE). This event, co-sponsored by the World Health Organization (WHO) and the Thai Ministry of Public Health, reviewed the progress made with vaccine development, sero-epidemiological studies and other accompanying activities critical for vaccine development and vaccination. The considerable interest in and awareness of the flavivirus diseases and their prevention by public health decision makers, as well as the establishment of two dedicated programmes for dengue and Japanese encephalitis vaccine development raise hopes that new or improved vaccines will become available in the coming years.

Diagnosis, Diagnostics, Immunodiagnosis & Immunodiagnostics:  

12570.        Chaturvedi UC, Shrivastava R. Dengue haemorrhagic fever: a global challenge. Indian J Med Microbiol 2004;22(1):5-6.

12571.    Thai KT, Binh TQ, Giao PT, Phuong HL, Hung le Q, Van Nam N, Nga TT, Groen J, Nagelkerke N, de Vries PJ. Seroprevalence of dengue antibodies, annual incidence and risk factors among children in southern Vietnam. Trop Med Int Health. 2005 Apr;10(4):379-86.

12572.    Upadhyay M, Singh S, Murlidharan J, Kaur N, Majumdar S. Randomized evaluation of fluid resuscitation with crystalloid (saline) and colloid (polymer from degraded gelatin in saline) in pediatric septic shock. Indian Pediatrics. 2005 Mar; 42(3): 223-231.

12573.    Venkata Sai PM, Dev B, Krishnan R. Role of ultrasound in dengue fever. Br J Radiol. 2005 May;78(929):416-8.

Pathogenesis:

12574.   Anantapreecha S, Chanama S, A-nuegoonpipat A, Naemkhunthot S, Sa-Ngasang A, Sawanpanyalert P, Kurane I. Serological and virological features of dengue fever and dengue haemorrhagic fever in Thailand from 1999 to 2002. Epidemiol Infect. 2005 Jun;133(3):503-7.

12575.    Calisher CH. Persistent emergence of dengue. Emerg Infect Dis. 2005 May;11(5):738-9.

12576.    Chen RF, Liu JW, Yeh WT, Wang L, Chang JC, Yu HR, Cheng JT, Yang KD.  Altered T helper 1 reaction but not increase of virus load in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol. 2005 Apr 1;44(1):43-50.

12577.   Kwan WH, Helt AM, Maranon C, Barbaroux JB, Hosmalin A, Harris E, Fridman WH, Mueller CG. Dendritic cell precursors are permissive to dengue virus and human immunodeficiency virus infection. J Virol. 2005 Jun;79(12):7291-9.

12578.    Nguyen TH, Nguyen TL, Lei HY, Lin YS, Le BL, Huang KJ, Lin CF, Do QH, Vu TQ, Lam TM, Yeh TM, Huang JH, Liu CC, Halstead SB. Association between sex, nutritional status, severity of dengue hemorrhagic fever, and immune status in infants with dengue hemorrhagic fever. Am J Trop Med Hyg. 2005 Apr;72(4):370-4.

12579.    Reyes-Del Valle J, Chavez-Salinas S, Medina F, Del Angel RM. Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. J Virol. 2005 Apr;79(8):4557-67.

12580.    Rodriguez-Roche R, Alvarez M, Gritsun T, Halstead S, Kouri G, Gould EA, Guzman MG. Virus evolution during a severe dengue epidemic in Cuba, 1997. Virology. 2005 Apr 10;334(2):154-9.

12581.    Sakuntabhai A, Turbpaiboon C, Casademont I, Chuansumrit A, Lowhnoo T, Kajaste-Rudnitski A, Kalayanarooj SM, Tangnararatchakit K, Tangthawornchaikul N, Vasanawathana S, Chaiyaratana W, Yenchitsomanus PT, Suriyaphol P, Avirutnan P, Chokephaibulkit K, Matsuda F, Yoksan S, Jacob Y, Lathrop GM, Malasit P, Despres P, Julier C. A variant in the CD209 promoter is associated with severity of dengue disease.Nat Genet. 2005 May;37(5):507-13.

Vaccines:

12582.      Hombach J, Barrett AD, Cardosa MJ, Deubel V, Guzman M, Kurane I, Roehrig JT, Sabchareon A, Kieny MP. Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. Vaccine. 2005 Apr 15;23(21):2689-95.

12583.    Stephenson JR. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ. 2005 Apr;83(4):308-14.

Therapy:

12584.   Blaney JE Jr, Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol. 2005 May;79(9):5516-28.

12585.    Huang CY, Silengo SJ, Whiteman MC, Kinney RM. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus. J Virol. 2005 Jun;79(12):7300-10.

Back